- Home
- Latest news
Latest news
Using your own cells to fight cancer
Cell therapy is bringing the world one step closer to eliminating cancer. Here’s how Johnson & Johnson is moving this cutting-edge therapy forward.
Johnson & Johnson named to Fortune‘s 2025 America’s Most Innovative Companies list
The company’s commitment to developing solutions that tackle the world’s most pressing health challenges has helped Johnson & Johnson be recognized as the top-ranked healthcare company on the list.
More from Johnson & Johnson
The future of immunology
Learn about the advances Johnson & Johnson is making to potentially help treat the millions of people living with conditions in which the immune system mistakenly damages healthy cells in the body.
Meet two Johnson & Johnson nurse educators dedicated to teaching cancer care providers
Jennifer Huff and Jacqui Mellott are two of Johnson & Johnson’s oncology clinical educators—a team of 50 nurses who visit hospitals and infusion centers to help providers understand and stay up to date with treatments.
Careers
Looking for a career opportunity at Johnson & Johnson? Search our available jobs.
Inside Johnson & Johnson’s decades-long quest to develop effective treatments for IBD
Inflammatory bowel disease doesn’t have a cure—yet. But the recent FDA approval of a promising medication is the latest in a long line of treatments from Johnson & Johnson that are helping patients with IBD.
What is metastatic cancer?
The number of people living with this advanced form of cancer is on the rise. Learn how Johnson & Johnson is pioneering innovations to help patients live longer.
“The surgical devices I design help speed healing and save lives”
Candice Otrembiak’s work combines her love of science with her natural problem-solving skills. The result: high-tech devices that help make medical procedures more efficient for surgeons and safer for patients.
Press releases
Johnson & Johnson showcases latest advancements in cancer innovation with more than 70 clinical and real-world studies at ASCO and EHA
New CARVYKTI® data help shift the treatment paradigm in relapsed or refractory multiple myeloma with five-year progression-free survival rates Late-breaking AKEEGA® data selected for ASCO Press Program, showcasing prostate cancer leadership and potential in patients with HRR-altered mCSPC Early results from next-generation molecules for leukemia, lymphoma, multiple myeloma and prostate cancer showcase pipeline strength
Johnson & Johnson MedTech Launches SOUNDSTAR CRYSTAL™ in the US, Redefining Image Clarity in 2D Intracardiac Imagingi
New ultrasound catheter delivers superior image quality,i,ii peak maneuverability and seamless CARTO™ 3 System integrationi, giving physicians improved visualizationii for added confidence during cardiac ablation procedures
U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma
ODAC recommendation based on the positive progression-free survival and clinical benefit in the Phase 3 AQUILA study If approved, DARZALEX FASPRO® would be the first treatment to potentially delay or prevent progression to multiple myeloma
Shockwave Medical Study Confirms Benefit of IVL-First Strategy in Real-World Female Patients with Complex Calcified Lesions in Late-Breaking Data Presentation at EuroPCR 2025
EMPOWER CAD, a global prospective, multi-center, real-world study, reaffirms favorable acute outcomes for coronary IVL in female patients, unlike other calcium modification tools
Shockwave Medical Highlights Commitment to Transform Treatment of Cardiovascular Disease at EuroPCR 2025
23 abstracts, including three late-breaking data presentations, to underscore the company’s scientific leadership in IVL and Reducer technology and the strength of its portfolio
